Related Experiment Video
Updated: Apr 30, 2026
Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice
Published on: January 7, 2019
Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an
Yeshwant Kurhe1, Radhakrishnan Mahesh, Deepali Gupta
1Department of Pharmacy, Birla Institute of Technology and Science, Pilani, 333031, Rajasthan, India, yashkurhe@gmail.com.
Abstract:
The biological mechanisms that link the development of depression to metabolic disorders such as obesity and diabetes remain ambiguous. In the present study the potential of a selective cyclooxygenase inhibitor celecoxib (15 mg/kg p.o.) was investigated in depression associated with obesity in mice. Behavioral tests used to assess depressive-like behavior were sucrose preference test, forced swim test (FST), tail suspension test (TST) and elevated plus maze (EPM). The basal locomotor score in obese mice was not altered. Furthermore, estimation of biochemical parameters was performed for plasma glucose, total cholesterol, triglycerides and total proteins. Escitalopram (10 mg/kg p.o.) served as reference standard drug. In the results, chronic treatment with celecoxib for 28 days significantly attenuated the behavioral alterations as indicated by increased the sucrose consumption, reduced the immobility time in FST and TST, increased the percent open arm time and entries in EPM in obese mice. In the biochemical parameters celecoxib significantly reversed the increased plasma glucose, total cholesterol, triglycerides and total proteins in obese mice. In conclusion, celecoxib exhibited potential antidepressant-like effect in depression associated with obesity, which to some extent is mediated by reversing the altered plasma glucose in obese mice.
Insights
Celecoxib, a cyclooxygenase inhibitor, demonstrated antidepressant effects in obese mice by improving depressive behaviors and reversing metabolic changes. This suggests a potential therapeutic role for celecoxib in managing obesity-related depression.
Area of Science:
- Neuroscience
- Pharmacology
- Metabolic Disorders
Background:
- The link between depression and metabolic disorders like obesity and diabetes is not fully understood.
- Obesity is often associated with increased risk and severity of depressive symptoms.
- Existing treatments may not fully address the complex interplay between metabolic health and mental well-being.
Purpose of the Study:
- To investigate the antidepressant potential of celecoxib, a selective cyclooxygenase inhibitor, in a mouse model of obesity-associated depression.
- To evaluate the effects of celecoxib on depressive-like behaviors and key biochemical parameters in obese mice.
Main Methods:
- Obese mice were treated with celecoxib (15 mg/kg) or escitalopram (10 mg/kg) for 28 days.
- Depressive-like behaviors were assessed using the sucrose preference test, forced swim test (FST), tail suspension test (TST), and elevated plus maze (EPM).
- Plasma glucose, total cholesterol, triglycerides, and total proteins were measured.
Main Results:
- Chronic celecoxib treatment significantly reduced depressive behaviors, including increased sucrose preference and reduced immobility in FST and TST.
- Celecoxib also improved anxiety-like behaviors, evidenced by increased exploration of open arms in the EPM.
- Biochemical analysis showed that celecoxib reversed elevated plasma glucose, total cholesterol, triglycerides, and total proteins in obese mice.
Conclusions:
- Celecoxib exhibits significant antidepressant-like effects in obese mice.
- These effects appear to be partly mediated by the reversal of altered metabolic parameters, particularly plasma glucose levels.
- Celecoxib shows promise as a potential therapeutic agent for depression associated with obesity.
Related Concept Videos
01:25Antidepressant Drugs: Overview
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs